Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

Alones Creative Approval has come late in Q2'24 I do note that current revenue estimates for VRNA for 2024 average just $7M, albeit from just six analysts. That doesn't sound like a particularly high bar to clear in the first six months of the launch. Of course those estimates could be revised upwards, and pale in comparison to a 2029 sales estimate of $1.05B GlobalData. Nonetheless is doesn't seem like a rapid launch is predicted, especially when we consider Ohtuvayre is priced at $35.4K annually. The comp ...